Despite the modest BBB uptake, [18F]NT431 represents an important step towards the future evaluation and development of CDK4/6 inhibitors or radioligands with superior BBB penetration for treatment and visualization of CDK4/6 positive cancers in the CNS. The gene discussed is CDK4; the disease is cancer.